KHC
24
4
LB
71
-2
ROST
60
-2
AES
49
-6
OMC
65
23
ADT
82
-2
ORCL
68
-4
TRV
56
4
AME
77
12
HES
40
-3
GIS
47
-2
WMB
60
-2
KEY
68
8
LOW
61
2
FOX
66
-4
SLB
38
-3
NRG
89
12
CLX
46
-3
PEG
60
2
EXPE
67
-2
KHC
24
4
LB
71
-2
ROST
60
-2
AES
49
-6
OMC
65
23
ADT
82
-2
ORCL
68
-4
TRV
56
4
AME
77
12
HES
40
-3
GIS
47
-2
WMB
60
-2
KEY
68
8
LOW
61
2
FOX
66
-4
SLB
38
-3
NRG
89
12
CLX
46
-3
PEG
60
2
EXPE
67
-2
Financhill
Back

Ascendis Pharma AS 10K Form

Sell
33

ASND
Ascendis Pharma AS

Last Price:
$161.59
Seasonality Move:
2.33%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ASND News And Ratings

See the #1 stock for the next 7 days that we like better than ASND

ASND Financial Statistics

Sales & Book Value

Annual Sales: $393.6M
Cash Flow: $-90.9M
Price / Cash Flow: 0
Annual Sales: $-3.40
Price / Book: 0

Profitability

EPS (TTM): -6.29300
Net Income (TTM): $-367.4M
Gross Margin: $345.7M
Return on Equity: -880.05%
Return on Assets: -34.81%

Ascendis Pharma AS Earnings Forecast

Key Ascendis Pharma AS Financial Ratios

  • The Gross Profit Margin over the past 6 years for ASND is 87.83%.
  • The Selling, General & Administrative Expenses for ASND have been equal to 78.25% of Gross Profit Margin.
  • The Research & Development expenses have been 84.43% of Revenue.
  • The Net Earning history of ASND is -103.97% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Ascendis Pharma AS Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ASND
CUSIP: 04351P
Website: ascendispharma.com

Debt

Debt-to-Equity Ratio: -4.46
Current Ratio: 1.04
Quick Ratio: 0.67

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 63.44

ASND Technical Analysis vs Fundamental Analysis

Sell
33
Ascendis Pharma AS (ASND) is a Sell

Is Ascendis Pharma AS a Buy or a Sell?